Kristin Yarema - Mar 1, 2022 Form 4 Insider Report for Atara Biotherapeutics, Inc. (ATRA)

Role
Chief Commercial Officer
Signature
/s/ David Tucker, Attorney-in-Fact for Kristin Yarema
Stock symbol
ATRA
Transactions as of
Mar 1, 2022
Transactions value $
$0
Form type
4
Date filed
3/3/2022, 06:02 PM
Previous filing
Jun 15, 2021
Next filing
Apr 12, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ATRA Common Stock Award $0 +45.5K +36.17% $0.00 171K Mar 1, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ATRA Employee Stock Option (Right to Buy) Award $0 +85.6K $0.00 85.6K Mar 1, 2022 Common Stock 85.6K $10.21 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These restricted stock units vest in 16 equal quarterly installments on each Company Quarterly Vesting Date (as defined below), with the initial installment vesting on May 15, 2022, subject to the reporting person's continuous service. Company Quarterly Vesting Date means March 1, May 15, August 15 and November 15 of each year.
F2 1/48th of the shares subject to the stock option vest and become exercisable each month with the initial installment vesting on April 1, 2022, subject to the reporting person's continuous service.